Atrial Fibrillation

Atrial Fibrillation – High-Yield Study Guide for Medical Students

Definition

Atrial fibrillation (AF) is a supraventricular tachyarrhythmia characterized by disorganized, rapid atrial electrical activity leading to ineffective atrial contraction and an irregularly irregular ventricular rhythm on ECG, typically without distinct P waves.

Epidemiology

Atrial fibrillation is the most common sustained cardiac arrhythmia worldwide and a major cause of stroke, heart failure, and cardiovascular mortality.[1] Its prevalence increases sharply with age and is higher in patients with structural heart disease, hypertension, and diabetes.

• Prevalence rises from <1% in young adults to >10% in those >80 years.
• More common overall in men, but women have a higher risk of AF-related stroke and mortality once AF is present.[1]
• Frequently coexists with heart failure; AF and HF share risk factors and worsen each other’s prognosis.[2]

Pathophysiology

AF results from a complex interplay of triggers and a vulnerable atrial substrate that supports multiple re-entrant wavelets.

• Triggers
  • Most commonly originate from myocardial sleeves in the pulmonary veins, which can exhibit focal ectopic firing.
  • Autonomic influences (sympathetic or vagal) can facilitate ectopic activity and initiate AF episodes.
• Atrial substrate
  • Chronic pressure or volume overload (e.g., hypertension, valvular disease, heart failure) causes atrial dilation and fibrosis.
  • Fibrosis disrupts normal conduction pathways, promoting re-entry and conduction heterogeneity.
  • Inflammation, oxidative stress, and neurohormonal activation further remodel atrial tissue.
• Electrical remodeling
  • Prolonged AF leads to shortening of atrial effective refractory period and changes in ion channel expression.
  • This creates a vicious cycle: “AF begets AF”—the longer AF persists, the more self-sustaining it becomes.
• Sex differences
  • Structural and hormonal differences, as well as comorbidity patterns, contribute to sex-specific AF risk and outcomes.[1]

Loss of coordinated atrial contraction impairs ventricular filling and leads to stasis of blood in the left atrial appendage, predisposing to thrombus formation and embolic stroke.

Clinical Presentation

AF may be asymptomatic or present with a range of cardiovascular and systemic symptoms.[3]

• Common symptoms
  • Palpitations – often described as rapid, irregular, or “fluttering” heartbeats.[3]
  • Dyspnea or reduced exercise tolerance.
  • Fatigue, weakness, or decreased stamina.
  • Dizziness, lightheadedness, or presyncope.
  • Chest discomfort or tightness (especially in patients with CAD).
• Signs on examination
  • Irregularly irregular pulse with varying pulse volume.
  • Variable intensity of first heart sound (S1).
  • Tachycardia may be present (AF with rapid ventricular response).
  • Signs of heart failure if decompensated (e.g., edema, JVP elevation, crackles).
• Complication-related presentations
  • Ischemic stroke or transient ischemic attack (sudden focal neurologic deficits).
  • Acute decompensated heart failure (pulmonary edema, orthopnea).

Classification

AF is often classified by temporal pattern, which has implications for management and prognosis.

• Paroxysmal AF – episodes terminate spontaneously or with intervention within 7 days (often <24 hours).
• Persistent AF – continuous AF lasting >7 days, requiring cardioversion for termination.
• Long-standing persistent AF – continuous AF >12 months with a rhythm-control strategy still considered.
• Permanent AF – AF accepted by patient and clinician; no further attempts at rhythm control.

Diagnosis

Electrocardiogram (ECG)

The ECG is the key diagnostic tool for AF.

• Diagnostic ECG features
  • Absence of discrete P waves.
  • Presence of fibrillatory (f) waves – irregular, low-amplitude oscillations best seen in leads V1, II, III, aVF.
  • Irregularly irregular RR intervals (unless AV node disease or pacing masks variability).

Further Evaluation

• History and physical
  • Define onset, triggers, comorbidities (HTN, HF, valvular disease, thyroid disease, alcohol use), and symptom burden.
• Laboratory tests
  • Electrolytes (K, Mg), renal function, liver function.
  • Thyroid function tests (screen for hyperthyroidism).
  • Consider BNP/NT-proBNP in suspected HF.
• Imaging and structural assessment
  • Transthoracic echocardiography (TTE) to assess left atrial size, left ventricular function, valvular disease, and pulmonary pressures.[2]
  • Transesophageal echo (TEE) when evaluating for left atrial appendage thrombus prior to cardioversion or ablation.
• Rhythm monitoring
  • Holter monitor or event recorder when AF is intermittent and not captured on initial ECG.[4]
  • Wearable devices and smartphone-based technologies can aid screening and detection of asymptomatic AF.[4]
• Risk stratification
  • Stroke risk: CHA₂DS₂-VASc score.
  • Bleeding risk: scores such as HAS-BLED (to guide but not dictate anticoagulation decisions).

Management Overview

Management of AF is built around three pillars: rate control, rhythm control, and thromboembolism prevention. Treatment is individualized based on symptoms, AF type, comorbidities, and stroke risk.[2][5]

Rate Control

The goal of rate control is to control ventricular rate and relieve symptoms without necessarily restoring sinus rhythm.

• Target
  • Lenient control: resting HR <110 bpm is acceptable in many stable patients.
  • Stricter HR targets (<80 bpm at rest) may be used if symptoms persist or LV dysfunction is present.
• First-line agents (choice depends on comorbidities)
  • Beta-blockers (e.g., metoprolol, bisoprolol) – preferred especially in patients with CAD or HFrEF.
  • Non-dihydropyridine calcium channel blockers (e.g., diltiazem, verapamil) – effective in patients without HFrEF.
  • Digoxin – useful in sedentary patients or as add-on in HF with reduced EF; less effective for rate control during exertion.
• AV node ablation with pacemaker
  • Considered in drug-refractory rate control with symptomatic AF and unsuitable for rhythm control.

Rhythm Control

Rhythm control aims to restore and maintain sinus rhythm using cardioversion, antiarrhythmic drugs, or catheter ablation. It is favored in patients with significant symptoms, younger age, or tachycardia-induced cardiomyopathy.

• Electrical cardioversion
  • Direct-current synchronized cardioversion is highly effective for terminating AF.
  • Requires proper anticoagulation or exclusion of atrial thrombus (via TEE) if AF duration >48 hours or unknown.
• Pharmacologic cardioversion and maintenance drugs
  • Class Ic agents (e.g., flecainide, propafenone) – for structurally normal hearts; avoid in significant structural heart disease or CAD.
  • Class III agents (e.g., amiodarone, sotalol, dofetilide where available) – used with consideration of proarrhythmic and organ-specific toxicities.
• Catheter ablation
  • Typically involves pulmonary vein isolation to eliminate AF triggers.[5]
  • Indicated for symptomatic AF refractory or intolerant to at least one antiarrhythmic drug, and increasingly considered earlier in selected patients, particularly with heart failure and reduced EF.
  • Catheter ablation can improve symptoms, quality of life, and in some populations may reduce HF-related outcomes.[2][5]

Stroke Prevention and Antithrombotic Therapy

Prevention of thromboembolism is central to AF management.

• Assess stroke risk
  • Use CHA₂DS₂-VASc (congestive HF, hypertension, age ≥75, diabetes, prior stroke/TIA, vascular disease, age 65–74, sex category).
  • Most men with score ≥2 and women with score ≥3 warrant chronic oral anticoagulation.
• Oral anticoagulants
  • Direct oral anticoagulants (DOACs) (e.g., apixaban, rivaroxaban, dabigatran, edoxaban) are generally preferred over warfarin in non-valvular AF due to similar or better efficacy and lower intracranial bleeding.
  • Warfarin remains indicated in patients with mechanical heart valves, moderate-to-severe rheumatic mitral stenosis, or certain specific conditions such as AF with obstructive hypertrophic cardiomyopathy where evidence is evolving.[6]
  • Time in therapeutic range (TTR) is crucial for warfarin effectiveness.
• Special situations
  • Left atrial appendage occlusion devices may be considered in patients with contraindications to long-term anticoagulation.
  • In patients undergoing PCI with stenting, strategies toward minimal combined antithrombotic regimens (shortened triple therapy, rapid transition to dual therapy) are emphasized to limit bleeding risk.[7]

AF in Heart Failure

AF and heart failure (especially HFrEF) frequently coexist, and their management must be integrated.

• AF can worsen HF through loss of atrial kick, rapid ventricular rate, and irregular filling.
• HF promotes AF through atrial dilation, fibrosis, and neurohormonal activation.
• Guideline-directed HF pharmacotherapy (ACEi/ARB/ARNI, beta-blocker, MRA, SGLT2i) should be optimized; these therapies can affect AF burden and outcomes.[2]
• Rate versus rhythm control decisions are influenced by HF type, symptom burden, and response to therapy; catheter ablation is increasingly used in HFrEF with symptomatic AF.[2]

Novel and Emerging Aspects

• Screening and detection
  • Wearables (smartwatches, patches) and smartphone-based ECG technologies are being integrated into AF screening strategies, especially in older adults and high-risk populations.[4]
• Risk factor modification
  • Weight loss, blood pressure control, treatment of sleep apnea, and reduced alcohol intake can significantly reduce AF burden and improve rhythm control outcomes.
• Dietary factors
  • The impact of n-3 fatty acids on AF risk is complex, with some data suggesting a potential increased risk at higher doses in certain populations, emphasizing the need for individualized assessment.[8]

Key Clinical Pearls for Exams and Practice

• Irregularly irregular rhythm with absent P waves on ECG = classic AF pattern; always think AF when you see this.
• AF is the most common sustained arrhythmia and a major cause of cardioembolic stroke; never forget stroke prevention.
• Always assess stroke risk (CHA₂DS₂-VASc) and bleeding risk when seeing a patient with AF.
• DOACs are preferred over warfarin for most patients with non-valvular AF, but warfarin remains essential for mechanical valves and rheumatic mitral stenosis.[6]
• Rate control is often sufficient in older, minimally symptomatic patients; rhythm control is prioritized in younger, symptomatic, or HF patients.
• In heart failure with reduced EF, choose beta-blockers for rate control and consider catheter ablation early in selected symptomatic patients.[2]
• Always check for reversible triggers: hyperthyroidism, electrolyte disturbances, acute infection, alcohol binge (“holiday heart”).
• For cardioversion when AF duration is >48 hours or unknown, ensure adequate anticoagulation or perform TEE to rule out left atrial thrombus.
• Remember the concept “AF begets AF”: early and effective control of AF and risk factors can prevent progression.
• Novel technologies (wearables, implantable loop recorders) are increasingly important for detecting silent AF, especially after cryptogenic stroke.[4]